Suven Life Sciences gets product patent to treat neurodegenerative ailments
DSIJ Intelligence / 21 Aug 2017
For the treatment of disorders associated with neurodegenerative diseases, Suven Life Sciences has been granted a product patent from Japan corresponding to the New Chemical Entities (NCEs).
For the treatment of disorders associated with neurodegenerative diseases, Suven Life Sciences has been granted a product patent from Japan corresponding to the New Chemical Entities (NCEs). These patents are valid through 2034.
The granted claims of the patents include the class of selective 5-HT4 compounds that are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s, Attention Deficient Hyperactivity Disorder (ADHD), Huntington’s Disease, Parkinson, and Schizophrenia.
Meanwhile, the stock was trading higher by 3.23% at Rs 166 per share on the BSE at 1123 hours. It opened at Rs 161.15 per share and attracted total traded volume of 3,30,883 shares and traded value of Rs 546.49 lakhs on the NSE at 1125 hours.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.